Heart Failure Due to Transthyretin Protein Amyloidosis
JAMA Clinical Reviews
00:00
Disease-Modifying Therapies Overview
Ruberg describes stabilizers that prevent misfolding and knockdown therapies (siRNA/ASO) that lower TTR production.
Play episode from 08:36
Transcript


